Immediate Rate‑Control Management of Stable New‑Onset Atrial Fibrillation

Hemodynamic Assessment of Stability

Adequate perfusion (systolic blood pressure ≈ 110 mm Hg), absence of chest pain or dyspnea, normal oxygen saturation, and preserved mental status define hemodynamic stability and support a pharmacologic rather than electrical approach. [1][3]

Immediate synchronized cardioversion is reserved for patients who are hemodynamically unstable (e.g., severe hypotension, shock, pulmonary edema, acute myocardial ischemia). [1][4][2][5]

In stable acute atrial fibrillation with rapid ventricular response, guideline‑endorsed first‑line therapy is rate control rather than rhythm conversion. [6][1]
Beta‑blockers are the preferred agents when left‑ventricular ejection fraction > 40 %, providing effective heart‑rate reduction and symptom relief. [6][2]

Drug	Initial Bolus	Titration / Repeat Doses	Comment
Metoprolol	2.5–5 mg IV over 2 min	Up to 3 total doses as needed	Short‑acting, widely available
Esmolol	500 µg/kg IV over 1 min	Continuous infusion 50–300 µg/kg/min	Very short half‑life, easily titratable

Dosing recommendations are based on American Heart Association (AHA) 2025 guidance. 2

If the ventricular rate is ≤ 150 beats/min in a stable patient, immediate cardioversion is not required; a brief trial of rate‑control medication is appropriate. 1

Intravenous diltiazem or verapamil (0.25 mg/kg IV bolus over 2 min) are effective alternatives, achieving 64–98 % success in controlling narrow‑complex tachyarrhythmias. [1][7]2
Digoxin may be used in the presence of hypotension, though it is less effective as a sole acute agent. [8][2]

For atrial fibrillation of < 48 h duration, early cardioversion is an option, but initial rate control remains the priority in stable patients. 5
If pharmacologic rate control fails or the patient remains highly symptomatic, delayed or immediate cardioversion can be pursued as a secondary strategy. [1][2]5

Anticoagulation should be started promptly in all patients with atrial fibrillation, irrespective of the immediate rate‑control plan. 5
When cardioversion is performed within 48 h of onset, it may be done without prior anticoagulation, but therapeutic anticoagulation must be continued for ≥ 4 weeks after cardioversion. [4][2]9

Avoid AV‑node‑blocking agents (beta‑blockers, calcium‑channel blockers, digoxin, adenosine) in patients with pre‑excitation syndromes (e.g., Wolff‑Parkinson‑White), as they can precipitate ventricular fibrillation. [3][2][10][5]
Do not proceed to immediate cardioversion in hemodynamically stable patients without first attempting pharmacologic rate control, to prevent unnecessary sedation risks. 1
Do not delay anticoagulation; initiate once adequate rate control is achieved. 5